When it comes to developmental drugs, there's a lot of rumors and speculation thrown around about a drug's ultimate success or failure in clinical trials. When the time comes for that hard data, share prices are bound to soar or plummet in a big way. That's what happened today with BioMarin (BMRN +0.00%), which published phase 3 data around its drug treating an ultra-rare disorder called Morquio A syndrome. Follow along in the video as Brenton Flynn and Max Macaluso discuss today's news and a couple more companies in a similar situation to BioMarin.
What's Behind BioMarin's Surge?
By Brenton Flynn and Max Macaluso – Nov 5, 2012 at 3:16PM
NASDAQ: BMRN
BioMarin Pharmaceutical

Market Cap
$10B
Today's Change
(0.36%) $0.19
Current Price
$53.26
Price as of October 21, 2025 at 1:00 PM ET
Phase 3 results are making the stock pop.